ALLE vs AVAV

ALLE's Advanced Deterministic Scorecard shows a Piotroski F-Score of 4/9, indicating stable but not strong financial health, while the absence of an Altman Z-Score prevents a definitive distress risk assessment. The company trades above its Graham Number of $61.34 at a current price of $166.80, reflecting a significant premium, though justified in part by solid profitability metrics including a 36.41% ROE and consistent earnings growth. Despite strong historical earnings surprises and solid margins, elevated valuation multiples and bearish insider activity temper upside potential. Analysts concur with a 'hold' recommendation, aligning with the neutral stance.

The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 0/9, indicating severe deterioration in core profitability, leverage, and operating efficiency. Despite explosive 150.7% year-over-year revenue growth and a bullish analyst consensus of 'strong_buy', the company is unprofitable (negative net and operating margins), burning equity (ROE of -2.64%), and trading at an elevated Forward P/E of 66.71. Persistent earnings misses over the last four quarters, declining YoY EPS, insider selling, and technical weakness in the short term (-21.7% weekly drop) further undermine valuation. While strong liquidity ratios suggest no immediate solvency risk, the lack of earnings quality and deteriorating fundamentals present substantial downside risk.